Shares of Shilpa Medicare rose over 3.5 percent in early trade on January 1 after the company received FDA approval for its Irinotecan Injection.
The Stock gained as much as 4.5 percent on the BSE, quoting at Rs 401.3.
The US Food and Drug Administration (USFDA) gave the company approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials.
Irinotecan injection is used to treat patients with metastatic cancer of the colon or rectum.
For more details click here – https://www.ways2capital.com
This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here